Human and animal drugs company, Dawa Limited, is planning to construct a US$ 30m drugs factory in Nairobi, Kenya. Installation of machinery at its Nairobi plant will also take place.
The firm’s Managing Director, Dr Ajay Patel, confirmed the reports and said that the new plant will lead to the growth of the company. Also, the expansion will enable them to serve 10 markets in East and West Africa.
Also Read: US$ 27m Mediclinic hospital under construction in South Africa
Mr Patel says shareholders are in talks with their financial advisors on the prospect of listing at the bourse to raise funds for further growth.
“Last year we achieved a US$ 20m turnover up from 2015’s US$ 17m which informs our strategy for expansion. We also plan to enter the Tanzanian market via a distribution network that we have now established,” said Mr Kumar.
The new plant
The new plant will furthermore enable the company to launch new lines of drugs. The drugs will be for easing pain and suffering among diabetic, hypertensive and Cardio-vascular patients among other lifestyle ailments; this is according to Dr Patel.
Currently, Dawa Limited has received Superbrands certification in the drugs category.
Customers across Kenya, Uganda, Burundi, Zambia, Malawi and Ivory Coast as well as in other Central and Western Africans countries were well-versed with Dawa’s products which they relied upon to treat various ailments and this initiative comes as a plus for to the company.
The Patel family has been at the helm of the drugs’ firm since 2004 when it had 20 employees to the current 400 employees.
Dawa Limited is one of the leading pharmaceutical manufacturers of human and veterinary medicines in Kenya and East Africa.
